Thromboxane B2 (TXB2)

Thromboxane B2 is an inactive, stable metabolic product of thromboxane A2, formed during platelet activation. It is a member of the eicosanoid lipid family and serves as a clinically important biomarker to monitor platelet function and the efficacy of antiplatelet therapies such as aspirin. Elevated levels in serum or urine are associated with increased risk of thrombotic events including ischemic stroke and myocardial infarction. Although biologically inactive and not itself a therapeutic target, its measurement supports clinical decision-making in cardiovascular disease management[2][3][4][5][8][9][10]. In summary, Thromboxane B2 is an inert lipid metabolite and not a canonical drug target, but it is routinely measured as a biomarker for platelet activity and antiplatelet drug efficacy, especially in cardiovascular and thrombotic disorders.

Other names

TXB2thromboxane B29α,11,15S-trihydroxythromba-5Z,13E-dien-1-oic acid(5Z,9α,13E,15S)-9,11,15-Trihydroxythromboxa-5,13-diene-1-oic acidCAS 54397-85-2

Not applicable for direct targeting; however, COX-1 inhibitors (e.g., aspirin) prevent thrombane A2 (and thus B2) formation by inhibiting arachidonic acid metabolism in platelets